Emergent BioSolutions closes $150 million term loan with OrbiMed, refinancing prior facility
PUBT · 16h ago
Share
Listen to the news
- Emergent BioSolutions closed new USD 150 million term loan with OrbiMed to refinance its prior term loan with Oak Hill Advisors.
- Wells Fargo amended Emergent’s asset-based revolving loan facility, lifting borrowing capacity to up to USD 50 million.
- Both facilities extend maturities to April 2031, pushing out prior 2029 maturities.
- New term loan cuts annual interest expense by 200 basis points.
- Refinancing adds flexibility through less restrictive covenants, expanded debt baskets, and a committed delayed-draw term loan option.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604161605PRIMZONEFULLFEED9691657) on April 16, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved